Project Grant HT94252510235

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $702,748 to Weill Medical College of Cornell University to research the role of neutrophils in anti-tumor immunity and immune-related adverse events associated with T cell-based cancer immunotherapies. The key objectives are to: 1) characterize the gene pathways and tumor-derived factors that define functional subsets of anti-tumorigenic neutrophils, 2) identify the clinically...

This $641,936.00 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to harness neutrophils, a type of white blood cell, and engineer them with chimeric antigen receptors (CARs) to treat glioblastoma, an aggressive form of brain cancer. The primary awardee, Purdue University, will develop and optimize neutrophil-specific CAR constructs, evaluate the antitumor activities of CAR-neutrophils combined with radiation or CAR-T cell therapy...

This federal Project Grant award of $636,222 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research at the University of Pittsburgh to investigate how immune checkpoint inhibitor-associated gut bacteria can modulate tumor immunity and enhance the efficacy of immune checkpoint inhibitor (ICI) therapy in melanoma. The key goals of the research are to: 1) Determine whether ICI-associated bacteria metabolize dietary tryptophan into aryl...

The National Cancer Institute (NCI) awarded a $684,877 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Icahn School of Medicine at Mount Sinai (ISMMS) to conduct a multi-scale analysis of the Bacillus Calmette-Guerin (BCG) resistant tumor microenvironment in non-muscle invasive bladder cancer. The 5-year project aims to generate a comprehensive molecular atlas of the bladder tumor microenvironment, leveraging single-cell sequencing and spatial transcriptomics, to...

The Department of the Army Medical Command awarded a $1,657,861 project grant to H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to develop adoptive T-cell therapy incorporating patient-specific tumor microenvironments for the treatment of bladder cancer. The grant was awarded on September 1, 2022 under the Military Medical Research and Development program (CFDA 12.420) and will support research activities through August 31, 2026. The Military Medical Research and...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Southern California provides $712,735 to conduct a Phase II randomized clinical trial evaluating the combination of the ephrinB2 inhibitor SEPHB4-HSA and the PD-1 antibody pembrolizumab in patients with muscle-invasive bladder cancer that expresses ephrinB2 and has low/no expression of nectin4. The study aims to determine the clinical outcomes, pathological complete response...

This $169,776 Project Grant award from the National Cancer Institute's (NCI) Cancer Research Manpower program (CFDA 93.398) supports research by the Fred Hutchinson Cancer Center in Seattle, Washington to investigate mechanisms of immunotherapy resistance in prostate cancer bone metastases. The key products and services to be delivered include: Utilizing mouse models and patient bone biopsies to determine if a specific granulocyte subset (CD62LhiCXCR2hi-Gran) mediates immunotherapy resistance...

The National Cancer Institute awarded a $1,542,555 Project Grant to Sloan-Kettering Institute For Cancer Research under the Cancer Treatment Research program (CFDA 93.395). The grant will fund research from December 2022 through November 2027 to develop more effective treatments for localized bladder cancer. Specifically, the grantee will conduct genomic analyses of bladder cancer patient cohorts to validate DNA damage response mutations as predictors of sensitivity to bacillus Calmette-Guérin...

This $641,336 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Ohio State University aims to advance immunotherapy for non-small cell lung cancer (NSCLC). The project will investigate how disrupting the GARP-TGFbeta axis in the tumor microenvironment using the anti-GARP antibody PIIO-1 can enhance CD8+ T cell function and overcome resistance to immune checkpoint blockade therapy in NSCLC patients. Key objectives include defining how GARP...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $583,973.00 to the Sloan-Kettering Institute for Cancer Research to investigate the role of EP300 mutations in bladder cancer pathogenesis and drug response. The key objectives are to: Study how EP300 loss-of-function mutations mediate resistance to FGFR inhibitors like erdafitinib using patient-derived bladder cancer models. Identify genomic alterations, especially EP300...